Form 4: Janux Therapeutics Director Granted Equity Awards, Including RSUs and Stock Options

Vickie L. Capps, a Director at Janux Therapeutics, Inc., was granted 3,750 Restricted Stock Units and options to purchase 11,667 shares of common stock on June 11, 2025.

Summary

• Vickie L. Capps, a Director of Janux Therapeutics, Inc. (JANX), acquired 3,750 shares of common stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 and will vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, contingent on Ms. Capps' continuous service.
• Ms. Capps also acquired options to purchase 11,667 shares of common stock at an exercise price of $25.46 per share on June 11, 2025.
• The stock options will vest in equal monthly installments over 12 months following June 11, 2025, or fully vest on the date of the next annual meeting of stockholders, also subject to continuous service.
• The stock options have an expiration date of June 10, 2035.
• Following these transactions, Ms. Capps beneficially owns 74,098 shares of common stock directly and 11,667 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is generally a positive sign of alignment and retention, but does not contain information that would significantly alter the company's fundamental outlook or financial performance. It's a neutral-to-mildly positive event.

Positives

• The grant of Restricted Stock Units and stock options to Director Vickie L. Capps aligns her interests with those of shareholders, incentivizing long-term performance and retention.
• The acquisition of equity by a director can be viewed as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for the granted Restricted Stock Units and stock options extend into the future, with RSUs vesting by June 11, 2026, or the next annual meeting, and stock options vesting over 12 months from June 11, 2025, or fully by the next annual meeting. The stock options have an expiration date of June 10, 2035, indicating a long-term incentive horizon.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across all industries, including the biotechnology sector. It reflects standard practices for incentivizing directors and aligning their interests with long-term company performance.

Comparison to Industry Standards

• The grant of RSUs and stock options to directors is a common compensation practice in the biotechnology and pharmaceutical industries, similar to companies like Amgen Inc. or Gilead Sciences, Inc., which frequently use equity awards to attract and retain top talent and align executive and director interests with shareholder value.
• The vesting schedules (e.g., 12-month monthly vesting for options, one-year cliff or next annual meeting for RSUs) are typical for director equity grants, comparable to those seen at peer companies in the small to mid-cap biotech space.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: While specific to a director, such compensation practices can reflect broader company policies on equity incentives, potentially impacting employee morale and retention.

Next Steps

• The Restricted Stock Units are expected to vest on the earlier of June 11, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• The stock options are expected to vest in equal monthly installments over the 12 months following June 11, 2025, or fully vest on the date of the next annual meeting of the Issuer's stockholders.
• The stock options will expire on June 10, 2035.

Key Dates

Keywords

Janux Therapeutics, JANX, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals